Seres Therapeutics, Inc. (MCRB)
2.94
+0.01
(+0.34%)
USD |
NASDAQ |
Oct 02, 16:00
2.93
-0.01
(-0.34%)
After-Hours: 20:00
Seres Therapeutics Gross Profit Margin (Quarterly) : 8.97% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 8.97% |
| March 31, 2026 | -118.2% |
| December 31, 2025 | -117.8% |
| September 30, 2025 | -197.4% |
| June 30, 2025 | |
| March 31, 2025 | |
| December 31, 2024 | |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | 97.07% |
| March 31, 2023 | |
| December 31, 2022 | -237.7% |
| September 30, 2022 | 12.89% |
| June 30, 2022 | -141.1% |
| March 31, 2022 | 0.00% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| Date | Value |
|---|---|
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| September 30, 2020 | 0.00% |
| June 30, 2020 | 0.00% |
| March 31, 2020 | 0.00% |
| December 31, 2019 | 0.00% |
| September 30, 2019 | 0.00% |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
| BioCryst Pharmaceuticals, Inc. | 98.01% |
| Imunon, Inc. | -- |
| Curis, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -61.75% |
| Return on Assets | -17.42% |
| Return on Invested Capital | -19.54% |
| Operating Margin (Quarterly) | -2.07K% |
| Return on Net Operating Assets | -27.29% |